Notes for P&L

All amounts in SEKm unless otherwise stated

Note 19 Non-current finanical assets


Download Excel

          Parent Company
Receivables from Group companies 2022-12-31 2021-12-31
Opening balance 6,589 1,709
Increase during the year 2,282 5,090
Decrease during the year -1,272 -210
Carrying amount at year-end 7,599 6,589
             
Specification of interests in Group companies Country Number of shares Quotient value Holding % Carrying amount 2022-12-31 Carrying amount 2021-12-31
AddLife Development AB Sweden 1,000 100 100% 389 389
 
Interests in Group companies Parent Company
Accumulated cost 2022 2021
Opening balance 389 389
Acquisitions for the year - 4,479
Disposals for the year¹ - -4,479
Closing balance 389 389
¹ Internal sale year 2021 of Primacy Healthcare 21 Limited and AddVision Holding GmbH.

Download Excel

Indirect ownership
Indirect ownership Ownership   Indirect ownership Ownership   Indirect ownership Ownership
Biomedica Medizinprodukte GmbH 100%   V-tech AB 100%   BioNordika (Denmark) A/S 100%
Euromed Swiss AG 100%   Väinö Korpinen Oy 100%   BioNordika Bergman AS 100%
Biomedis d.o.o. 100%   Triolab Oy 100%   BioNordika (Sweden) AB 100%
Biomedica MP d.o.o. 100%   Triolab AB 100%   BioNordika (Finland) Oy 100%
Biomedica Dijagnostika doo 100%   Triolab (Baltics) Oy 100%   Dach Medical Group Holding AG 100%
Biomedica d.o.o. 100%   LabRobot Products AB 100%   Dach Austria Medical Group GmbH 100%
Biomedica Bulgaria ood 100%   BergmanLabora AB 100%   Dach Switzerland Medical Group GmbH 100%
Biomedica Medizinprodukte Romania SRL 100%   Biolin Scientific AB 100%   D-A-CH Germany Medical Group GmbH 100%
Biomedica Hungaria Kft. 100%   Biolin Scientific China 100%   Hepro AS 100%
Biomedica CS s.r.o. 100%   Biolin Scientific Oy 100%   Ropox A/S 100%
Biomedica Poland Sp. Zo.o. 100%   Biolin Scientific LTD 100%   Zafe Care Systems AB 100%
Biomedica Dijagnostika d.o.o.el 100%   Holm & Halby A/S 100%   Biomedica Italia s.r.l 100%
Biomedica Slovakita s.r.o. 80%   Ocellus Vision Holding AG 100%   Primacy Healthcare 21 Limited 100%
Mediplast AB 100%   Medilas AG 100%   Aquilant Northern Ireland Limited 100%
Mediplast AS 100%   Polytech Ophthalmologie AG 100%   Aquilant Limited 100%
Mediplast Sataside Oy 100%   Polytech Domilens GmbH 100%   Medscope Limited 100%
Mediplast S.r.l 100%   M.E.D. Medical Products GmbH, Germany 100%   Aquilant Endoscopy Limited 100%
Mediplast Benelux B.V. 100%   Vision Ophthalmology Holding One GmbH 100%   Healtcare Acquisitions Limited 100%
Mediplast GmbH 100%   Vision Ophthalmology Group GmbH 100%   Tools For Living (Ireland) Limited 100%
Mediplast A/S 100%   Spectrum Ophthalmology Ltd 100%   Lyncare Systems Limited 100%
Mediplast Iberia SL 100%   POLYMED Polska Sp.z.oo 75%   Healthcare 21 (UK) Limited 100%
Hospidana A/S 100%   Visop Nordic AB 100%   Healthcare 21 (DE) GmbH 100%
Fenno Medical Oy 100%   SSCP Blink BidCo Ltd 100%   Healthcare 21 (AT) GmbH 100%
TechniPro PulmoMed Pty Ltd 100%   Vision Pharmaceuticals Ltd 100%   Primacy Healthcare 21 International Limited 100%
Fischer Medical AS 100%   MALA Holding B.V. 100%   Asset Tracker Solutions Limited 100%
Camanio AB 100%   Bio-Connect B.V. 100%   Aquilant Scientific (ROI) Limited 100%
Bestic AB 100%   Bio-Connect Diagnostics B.V. 100%   Aquilant Medical (ROI) Limited 100%
Lab-Vent Controls A/S 100%   Bio-Connect Services B.V. 100%   Xograph Healthcare Limited 100%
Immuno Diagnostics Oy 100%   European Warehousing Services B.V. 100%   Xograph Healthcare (Ireland) Limited 100%
Bergman Diagnostika AS 100%   Pharma-Connect B.V. 100%   Glanadh Medical Holdings Limited 100%
EuroClone S.p.A. 100%   N.V. Forlab SA 100%   O'Flynn Medical Limited 100%
Funksjonsutstyr AS 76%   MBA Incorporado S.L. 100%   O'Flynn Innovation Limited 100%
Svan Care AB 100%   MBA Italia S.R.L 100%   JK Lab AB 100%
Esthe-Tech AB 100%   MBA Portugal S.A. 100%   BioCat GmbH 100%

Accounting principle

Interests in Group companies are recognised in the Parent Company using the cost method, which means that transaction costs are included in the carrying amount for holdings in subsidiaries. Any changes in liabilities for contingent consideration are added to or reduce the (acquisition) cost. In the Group, transaction costs are expensed and changes in liabilities for contingent considerations are entered as income or expense. Shareholder contributions provided by the Parent Company are recognized in shares, when impairment is not required.  

To the top